Related Experiment Video
Updated: May 3, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
A quality study to improve prophylactic antithrombotic therapy prescribed to patients with atrial fibrillation
Rui Oliveira1, Sandra Grilo1, Carla Moreira1
1USF Infante D. Henrique, Viseu, Portugal.
Insights
Improving antithrombotic therapy for atrial fibrillation patients is crucial. An educational intervention increased appropriate prophylactic anticoagulation prescription rates from 49.5% to 60.0%.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Atrial fibrillation is a common arrhythmia linked to increased thromboembolic events and mortality.
- CHA2DS2-VASc and HAS-BLED scores guide antithrombotic therapy decisions.
- Optimizing prophylactic antithrombotic therapy is essential for patient outcomes.
Purpose of the Study:
- To evaluate and enhance the quality of antithrombotic therapy for atrial fibrillation patients.
- To assess the appropriateness of prescribed prophylactic anticoagulation.
- To implement a quality improvement cycle for better patient care.
Main Methods:
- A quality improvement study using an assessment-intervention-assessment cycle.
- Calculation of CHA2DS2-VASc and HAS-BLED scores for all patients.
- Educational intervention followed by a second assessment of therapy appropriateness.
Main Results:
- Initial assessment: 49.5% of patients received appropriate prophylactic therapy.
- Post-intervention: 60.0% of patients received appropriate therapy.
- A 21.2% improvement in appropriate therapy prescription was observed.
Conclusions:
- Inappropriate treatment was primarily due to under-prescription of oral anticoagulation.
- The quality improvement cycle is effective for continuous assessment and care enhancement.
- Improved adherence to scoring systems can optimize atrial fibrillation management.
Introduction:
Atrial fibrillation is the most common cardiac arrhythmia and has important clinical repercussions, increasing thromboembolic events and mortality. The CHA2DS2-VASc and HAS-BLED scores assist the clinician in assessing the benefits and risks of antithrombotic therapy.
Objective:
The aim of this study was to assess and improve the quality of prophylactic antithrombotic therapy prescribed to patients with atrial fibrillation.
Methods:
This was a quality study, based on a cycle of assessment and improvement, applied to the population of a family health unit, consisting of an initial assessment, an educational intervention and a second assessment. Both scores were calculated for all patients. Whenever the CHA2DS2-VASc score recommended initiation of anticoagulation, the risk was calculated by the HAS-BLED score; it was thus possible to determine for each patient if the prescribed therapy was appropriate.
Results:
The first assessment included 105 patients, of whom 49.5% had appropriate prophylactic therapy according to their scores. In the second assessment, four months after the educational intervention, 60.0% had been prescribed appropriate therapy, which represented a 21.2% improvement.
Conclusions:
In both assessments, inappropriate treatment was due to non-prescription of prophylactic oral anticoagulation. This quality cycle serves as a tool for continuous assessment in the pursuit of improved care for patients with atrial fibrillation.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:26Atherosclerosis III: Management
01:27Coronary Artery Disease V: Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins